Ascletis Pharma, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-389.00
-320.00
-137.00
-339.00
-218.00
-219.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
2.00
17.00
38.00
39.00
-12.00
11.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-366.00
-236.00
-159.00
-165.00
-177.00
-95.00
Cash Flow from Investing Activities
630.00
930.00
165.00
-1,508.00
-330.00
148.00
Cash Flow from Financing Activities
374.00
-112.00
-90.00
-1.00
-37.00
-24.00
Net Cash Inflow / Outflow
625.00
581.00
-81.00
-1,539.00
-582.00
-94.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
-12.00
0.00
2.00
136.00
-36.00
-123.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in HKD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Ascletis Pharma, Inc.
Figures in Million
consolidated Cash Flow Results
Change(HKD)
Change(%)
Profit Before Tax
-389.749501830073
349.757702534676
-738.00
-211.43%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
2.19290625560115
-129.672121343821
131.00
101.69%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-366.539617173238
229.394045281767
-595.00
-259.79%
Cash Flow from Investing Activities
630.116754576811
-104.390797048906
734.00
703.61%
Cash Flow from Financing Activities
374.405665181089
40.7553037483856
334.00
818.67%
Net Cash Inflow / Outflow
625.573686176854
159.485668804986
466.00
292.24%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
-12.4091164078083
-6.27288317625967
-6.00
-97.82%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is -54.97% vs -48.48% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-366.54
-236.53
-54.97%






